PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ... [Yahoo! Finance]
PTC Therapeutics, Inc. (PTCT)
Last ptc therapeutics, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ptcbio.com
Company Research
Source: Yahoo! Finance
Cash Position: Over $1.1 billion at year-end 2024, plus an additional $1 billion received in January 2025 from the Novartis PTC518 transaction. DMD Franchise Revenue: $547 million for the full year 2024. Evrysdi Royalty Revenue: $204 million for the full year 2024. Non-GAAP R&D Expense (Q4 2024): $116 million, excluding $9 million in noncash stock-based compensation. Non-GAAP SG&A Expense (Q4 2024): $76 million, excluding $8 million in noncash stock-based compensation. 2025 Revenue Guidance: $600 million to $800 million. 2025 Non-GAAP R&D and SG&A Expense Guidance: $730 million to $760 million, excluding $75 million in noncash stock-based compensation. Warning! GuruFocus has detected 4 Warning Sign with PTCT. Release Date: February 27, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points PTC Therapeutics Inc ( NASDAQ:PTCT ) reported strong financial performance in 2024, with fourth quarter reven
Show less
Read more
Impact Snapshot
Event Time:
PTCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTCT alerts
High impacting PTC Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTCT
News
- Principal Spectrum Preferred Secs Active ETF declares monthly distribution of $0.0827 [Seeking Alpha]Seeking Alpha
- Principal Investment Grade Corporate Active ETF declares monthly distribution of $0.0792 [Seeking Alpha]Seeking Alpha
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- PTC Therapeutics (NASDAQ:PTCT) was downgraded by analysts at Royal Bank Of Canada from an "outperform" rating to a "sector perform" rating.MarketBeat
PTCT
Earnings
- 11/4/25 - Beat
PTCT
Sec Filings
- 12/5/25 - Form 4
- 12/4/25 - Form SCHEDULE
- 12/3/25 - Form 4
- PTCT's page on the SEC website